Cardinal Health

Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Physician, FDA, Gout, Cardinal Health, Chronic pain, United, Negotiation, Nursing

GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Key Points: 
  • GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
  • Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States¹.
  • The increase of GLOPERBA® manufacturing is to meet its potential demand and increased stocking needs in its distribution center.
  • For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .

National Association of Manufacturers Names FourKites Executive Dan Abramson to Board of Directors

Retrieved on: 
Giovedì, Marzo 7, 2024
Technology, Trucking, Maritime, Air, Transport, Software, Data Management, Logistics, Supply Chain Management, Retail, Dow Chemical Company, Senior, National Association, Rio Tinto, Abramson, Quality of life, SAS, B2B, GM, Cardinal Health, ExxonMobil, Human, Organization, Ecosystem, General Mills, Policy, NAM, Workforce, Dow, Management

Leading real-time supply chain visibility provider FourKites ® today announced the appointment of Dan Abramson, Senior Vice President and Head of Sales, to the Board of Directors of the National Association of Manufacturers (NAM).

Key Points: 
  • Leading real-time supply chain visibility provider FourKites ® today announced the appointment of Dan Abramson, Senior Vice President and Head of Sales, to the Board of Directors of the National Association of Manufacturers (NAM).
  • Founded in 1895, the NAM, guided by its Board of Directors, is the largest industrial trade association in the United States.
  • NAM selected FourKites to join its board because of the company’s transformational impact on the manufacturing industry's supply chain operations.
  • “This board appointment is an exciting opportunity for FourKites to elevate the importance of data and digital transformation across US manufacturing.

Cardinal Health annual research report examines milestone year in biosimilars

Retrieved on: 
Giovedì, Febbraio 29, 2024
Retina, Ophthalmology, Adalimumab, Cardinal Health, MBA, Research, Doctor of Pharmacy, Patient, Generic drug

DUBLIN, Ohio, Feb. 29, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars. The publication highlights legislative developments and new treatments, including adalimumab biosimilars. The report also provides the perspectives of retina specialists on biosimilars, ahead of the expected launch of multiple new biosimilars for retinal diseases.

Key Points: 
  • DUBLIN, Ohio, Feb. 29, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars.
  • The report also provides the perspectives of retina specialists on biosimilars, ahead of the expected launch of multiple new biosimilars for retinal diseases.
  • The report examines a year of major developments in biosimilars, offering expert commentary and provider perspectives on a rapidly changing industry landscape.
  • With 2024 expected to be a critical year for retina biosimilars, Cardinal Health surveyed providers in ophthalmology to obtain perspectives that may influence adoption while highlighting continued obstacles to wider use of biosimilars.

Bob Azelby to join Cardinal Health Board of Directors

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Amgen, Cardinal Health, MBA, ADC, Juno Therapeutics, University, Therapy, Organization, CAH, Harvard Business School, Religious studies, Clovis Oncology, Lundbeck Seattle Biopharmaceuticals, Management

DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.

Key Points: 
  • DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.
  • Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries.
  • Mr. Azelby currently serves on the Boards of Directors of ADC Therapeutics and Autolus Therapeutics.
  • "Bob Azelby is a highly respected healthcare industry leader with a strong track record of leading large, complex organizations as both a CEO and a board member," said Greg Kenny, Chairman of the Board for Cardinal Health.

Crown Castle Co-Founder Ted B. Miller Files Lawsuit to Invalidate Crown Castle's Unlawful Cooperation Agreement with Elliott

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Boot, Participation, Crown Castle, ANY, Common stock, WHEN, Cardinal Health, Common, Tenant, Annual general meeting, GOLD, Security (finance), WRCB, UPON, Corporation, AS, Investment

HOUSTON, Feb. 28, 2024 /PRNewswire/ -- Ted B. Miller, co-founder of Crown Castle Inc. (NYSE: CCI) ("Crown Castle" or the "Company") and his investment vehicle Boots Capital Management, LLC ("Boots Capital") today filed a complaint in the Court of Chancery of the State of Delaware (the "Court") seeking to invalidate the cooperation agreement between Crown Castle's Board of Directors (the "Board") and Elliott Investment Management, L.P. (together with its affiliates, "Elliott") announced on December 20, 2023. Under the terms of the cooperation agreement, Elliott and the Company appointed two new directors, Jason Genrich, Partner at Elliott, and Sunit Patel, Chief Financial Officer of Ibotta Inc. (collectively, the "Elliott Directors"), to the Board. Elliott received substantial governance rights without the customary provision that it be required to maintain an equity ownership position in the Company.1

Key Points: 
  • Similarly, statements that describe the Participants' (as defined below) objectives, plans or goals are forward-looking.
  • There can be no assurance that any idea or assumption herein is, or will be proven, correct.
  • IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.
  • 1 For example, Pinterest, Inc. entered into a cooperation agreement with Elliott on December 6, 2022, and Cardinal Health, Inc. entered into a cooperation agreement with Elliott on September 5, 2022, which each required that Elliott maintain an equity ownership threshold of 4.3% and 2.25%, respectively.

LSPedia Unveils OneScan 7.1: A Leap into the Future of Pharma Traceability and Compliance

Retrieved on: 
Lunedì, Febbraio 19, 2024
Cloud, FSMA, VRS, Friction, DSCSA, EPCIS, Cardinal Health, Supply, Data wrangling, NABP, 7.1 surround sound, CGMP, Veterans' affairs, WMS

OneScan 7.1 is a transformative upgrade with cutting-edge capabilities that redefine global traceability, compliance, and supply chain efficiency.

Key Points: 
  • OneScan 7.1 is a transformative upgrade with cutting-edge capabilities that redefine global traceability, compliance, and supply chain efficiency.
  • OneScan 7.1 introduces state-of-the-art global traceability features that empower pharmaceutical companies with an unprecedented ability to track and manage products on a global scale.
  • Compliance remains at the forefront of OneScan 7.1, boasting significant enhancements in the Compliance Cloud.
  • Riya Cao, the visionary CEO of LSPedia, expressed her excitement about the release stating "OneScan 7.1 is a game-changer for LSPedia and the pharmaceutical industry.

binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io

Retrieved on: 
Lunedì, Febbraio 12, 2024
Cardinal, Hospital, POC, FDA, Infection, Female, Pharmacy, Cardinal Health, Emergency, World Congress, Patient, CLIA, Diagnosis, Male, Gonorrhea, Chlamydia, STI, Medical imaging

Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.

Key Points: 
  • Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.
  • We are proud that we have earned their trust in binx and the binx io," said Jeffrey Luber, binx health’s Chief Executive Officer.
  • With this distribution collaboration, together binx health and Cardinal Health teams will help improve access to the treatment of CT/NG.
  • For more information about the binx io, visit mybinxhealth.com/binx-io or contact your Cardinal Health representative.

Leading Healthcare Strategist Jeff Moser Joins Compass One Healthcare

Retrieved on: 
Giovedì, Febbraio 8, 2024
Managed Care, Hospitals, Health, Practice Management, Strategic planning, Economics, Psychology, Compass One, Texas Christian University, Senior, Hospital, Compass, Springfield College, Cardinal Health, CHI, Nursing

Jeff Moser, a leading healthcare strategist with over 30 years of experience, has joined Compass One Healthcare (Compass One) as the Senior Vice President of Partner Strategy.

Key Points: 
  • Jeff Moser, a leading healthcare strategist with over 30 years of experience, has joined Compass One Healthcare (Compass One) as the Senior Vice President of Partner Strategy.
  • In his new role, Moser leads Compass One’s partner engagement strategy, focusing on identifying new opportunities, creating value, and growing existing relationships with hospitals and health systems.
  • “Jeff knows the key drivers of health system financial, operational, and clinical performance, and he is known for being a trusted advisor to healthcare C-Suite executives and critical decision-makers,” said Compass One chief executive officer Bobby Kutteh.
  • During his time at Sg2, Moser was a trusted advisor to Compass One on critical drivers of health system financial, operational, and clinical performance.

AtScale Releases Keynote Lineup, Full Agenda and Registration for 2024 Semantic Layer Summit

Retrieved on: 
Mercoledì, Febbraio 7, 2024
Professional Services, Data Management, Technology, Data Analytics, Software, Artificial Intelligence, Cloud, Knowledge, Cardinal Health, T-Mobile, Synthetic media, Netflix, Content, Ecosystem, Principle, Former, Generative, Google Cloud, EST, Snowflake, Management

AtScale , the leading provider of semantic layer solutions for analytics and generative AI, today announced the keynote line up for its Semantic Layer Summit .

Key Points: 
  • AtScale , the leading provider of semantic layer solutions for analytics and generative AI, today announced the keynote line up for its Semantic Layer Summit .
  • This event marks the third-annual Summit, drawing over 8,000 registrants and featuring speakers from across the industry.
  • Attendees can expect to hear from top industry experts, researchers, and practitioners as they share best practices and personal experiences.
  • Semantic Layer Summit’s featured keynote delivered by AtScale’s co-founder and CTO David P. Mariani and AtScale’s Head of Product, Elif Tutuk, will explore important new innovations in semantic layer platforms as it relates to the concepts of composable semantic modeling, decentralized data product innovation, and ecosystem integration.

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

Retrieved on: 
Martedì, Febbraio 6, 2024
Laboratory, Growth, McKesson Corporation, Patient, Cardinal Health, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.

Key Points: 
  • NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.
  • Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician owned laboratories.
  • “The addition of this agreement with Cardinal Health, and alongside distribution agreements Precipio has with Fisher Healthcare and McKesson, strengthens our distribution network and positions us for growth in 2024”, said Ilan Danieli, Precipio’s CEO.
  • “Cardinal Health is a formidable player in the market, and we are excited to work with them to deliver value to their customers, and to the patients they serve”.